A023910 Stock Overview
Engages in the manufacture and sale of therapeutic drugs in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for A023910 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Daihan Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩26,850.00 |
| 52 Week High | ₩29,650.00 |
| 52 Week Low | ₩23,750.00 |
| Beta | 0.19 |
| 1 Month Change | 3.27% |
| 3 Month Change | 2.29% |
| 1 Year Change | -4.11% |
| 3 Year Change | -5.62% |
| 5 Year Change | -14.22% |
| Change since IPO | 616.00% |
Recent News & Updates
Recent updates
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly
Mar 02
Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Feb 09
Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?
Jan 19What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?
Dec 18Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?
Nov 27Shareholder Returns
| A023910 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.1% | -1.7% | -3.7% |
| 1Y | -4.1% | 0.1% | -10.4% |
Return vs Industry: A023910 underperformed the KR Pharmaceuticals industry which returned 0.1% over the past year.
Return vs Market: A023910 exceeded the KR Market which returned -10.4% over the past year.
Price Volatility
| A023910 volatility | |
|---|---|
| A023910 Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A023910 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A023910's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | n/a | Sungyoung Lee | www.daihan.com |
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions.
Daihan Pharmaceutical Co.,Ltd. Fundamentals Summary
| A023910 fundamental statistics | |
|---|---|
| Market cap | ₩157.88b |
| Earnings (TTM) | ₩30.67b |
| Revenue (TTM) | ₩201.97b |
5.1x
P/E Ratio0.8x
P/S RatioIs A023910 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A023910 income statement (TTM) | |
|---|---|
| Revenue | ₩201.97b |
| Cost of Revenue | ₩133.95b |
| Gross Profit | ₩68.02b |
| Other Expenses | ₩37.36b |
| Earnings | ₩30.67b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.22k |
| Gross Margin | 33.68% |
| Net Profit Margin | 15.18% |
| Debt/Equity Ratio | 0% |
How did A023910 perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yieldn/a
Payout RatioDoes A023910 pay a reliable dividends?
See A023910 dividend history and benchmarks| Daihan PharmaceuticalLtd dividend dates | |
|---|---|
| Ex Dividend Date | Dec 27 2024 |
| Dividend Pay Date | Apr 18 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 117 days |
Does A023910 pay a reliable dividends?
See A023910 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daihan Pharmaceutical Co.,Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jang-wook Park | Daishin Securities Co. Ltd. |
| Hong-Sik Jeong | LS Securities Co., Ltd. |